Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Griesinger

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 29, 2021
Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184]Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2020
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Future Oncology (London, England)|November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW studyFrank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER TrialGerhard Held, Lorenz Thurner, Viola Poeschel, et al.
The New England Journal of Medicine|October 4, 2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung CancerD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
The Oncologist|January 23, 2025
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancerFerdinandos Skoulidis, Bob T Li, Maximilian Hochmair, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in GermanyJan A Stratmann, Friederike C Althoff, Paula Doebel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical PracticeXiuning Le, Hiroshi Sakai, Enriqueta Felip, et al.
European Journal of Cancer (Oxford, England : 1990)|October 18, 2024
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapyFelix Carl Saalfeld, Johanna Möller, Petros Christopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2022
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertionsPetros Christopoulos, Klaus Kluck, Martina Kirchner, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Lung Cancer (Amsterdam, Netherlands)|May 29, 2021
Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184]Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2020
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Future Oncology (London, England)|November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW studyFrank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER TrialGerhard Held, Lorenz Thurner, Viola Poeschel, et al.
The New England Journal of Medicine|October 4, 2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung CancerD Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
The Oncologist|January 23, 2025
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancerFerdinandos Skoulidis, Bob T Li, Maximilian Hochmair, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in GermanyJan A Stratmann, Friederike C Althoff, Paula Doebel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical PracticeXiuning Le, Hiroshi Sakai, Enriqueta Felip, et al.
European Journal of Cancer (Oxford, England : 1990)|October 18, 2024
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapyFelix Carl Saalfeld, Johanna Möller, Petros Christopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|May 22, 2022
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertionsPetros Christopoulos, Klaus Kluck, Martina Kirchner, et al.
Pageof 16